OGN
Organon & Co.Pharmaceuticals, Biotechnology & Life Sciences
- Rank · 2026
- #185
- Final score
- 61.74
- Years on list
- 5
↗ Climbed 740 since 2022
Compare · Up to four Russell 1000 companies
Select two, three, or four Russell 1000 companies to compare their overall rank, year-by-year trajectory, and scores down to the category level.
Figure 01 · Side-by-side summary
Pharmaceuticals, Biotechnology & Life Sciences
↗ Climbed 740 since 2022
Pharmaceuticals, Biotechnology & Life Sciences
↗ Climbed 319 since 2020
Pharmaceuticals, Biotechnology & Life Sciences
↘ Down 90 since 2020
Figure 02 · Rank trajectory
Lower is better. The y-axis is inverted so a rising line means an improving rank. Missing years mean the company didn't make the top 100 that year.
Figure 03 · Pillar profile · 2026
Latest-year ESG pillar scores, 0–100. The shaded bar shows relative strength across the selected companies for each pillar.
| Pillar | OGN | QGEN | REGN |
|---|---|---|---|
| Climate Change | 67.8 | 89.0 | 71.1 |
| Employee Relations | 62.0 | 65.9 | 54.3 |
| Environment | 60.2 | 42.2 | 57.9 |
| Stakeholders & Society | 62.3 | 34.3 | 61.9 |
| Human Rights | 60.0 | 70.7 | 57.2 |
| Governance | 52.9 | 66.9 | 54.6 |
| Performance Rating | 57.7 | 63.9 | 71.7 |